

# [Roche to acquire LumiraDx's POC technology](#)

written by CAP TODAY

March 19, 2024

March 2024—Roche has entered into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx's point-of-care technology. The transaction is expected to close by the middle of this year, after which the acquired entities will be fully integrated into Roche Diagnostics.

Roche says the acquired technology platform offers a range of immunoassay and clinical chemistry tests and the potential for additional tests in the future.

"The addition of the LumiraDx technology to our diagnostic portfolio will enable us to transform testing at the point of care," Matt Sause, Roche Diagnostics CEO, said in a press statement.

[Roche](#), +41 61 688 8888



©2026 CAP TODAY, all rights reserved.